NovoCure Chairman Sells Over $900K in Shares

Insider selling raises concerns about the medical device company's outlook

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

NovoCure Limited (NASDAQ:NVCR) Chairman William Doyle sold 71,887 shares of the company's stock, worth approximately $933,000, in a transaction on Tuesday, March 3rd. The sale represents a 17.96% decrease in Doyle's ownership stake in the medical device firm, which develops a novel cancer treatment technology called Tumor Treating Fields.

Why it matters

Insider selling, especially by a company's chairman, can be seen as a negative signal by investors about the firm's future prospects. The large volume of the sale by Doyle, along with additional selling by other NovoCure executives, may raise concerns about the company's outlook despite its innovative cancer treatment technology.

The details

In the transaction, Doyle sold the shares at an average price of $12.98, reducing his total holdings to 328,397 shares valued at around $4.26 million. The sale was disclosed in a filing with the Securities and Exchange Commission. In addition to Doyle's sale, several other NovoCure insiders executed notable transactions this week, including the COO, CEO, CFO, and other executives, further contributing to the negative sentiment around the stock.

  • On March 3, 2026, Chairman William Doyle sold 71,887 shares of NovoCure stock.

The players

William Doyle

The chairman of NovoCure Limited, a medical device company that develops a novel cancer treatment technology called Tumor Treating Fields.

NovoCure Limited

A global oncology company that pioneered Tumor Treating Fields (TTFields), a non-invasive anti-mitotic therapy for solid tumors.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The significant insider selling by NovoCure's chairman and other top executives raises concerns about the company's outlook, despite its innovative cancer treatment technology. Investors will be closely watching for any further developments or changes in sentiment around the stock.